In this free webinar, gain insights into 1859’s approach to generating high-quality empirical training data, while maintaining diversity, density and scale. The featured speakers will share case studies that demonstrate how high-quality empirical data augments drug discovery. Attendees will learn how this approach compares to other types of data generation in the biopharmaceutical industry.

TORONTO, Nov. 16, 2023 /PRNewswire-PRWeb/ — The transformative impact of artificial intelligence (AI) on various industries is undeniable. However, for the biopharmaceutical industry, AI has yet to meet its full potential. The significant barrier that remains in bringing an AI revolution to drug discovery is the scarcity of high-quality, biologically relevant training data.

In this webinar, 1859 will discuss its approach to rapidly generating high-quality, empirical, small molecule datasets, and its comparison to other approaches, like public data curation and traditional screening technology. In addition, the panel will walk through case studies that show how this data accelerates drug discovery at Hit ID through Lead OP.

1859’s discovery engine has the capacity to generate millions of active and inactive data points with embedded structure-activity relationships (SAR). To generate high-quality datasets, AI is used to inform diversity or focused library design of drug-like, combinatorial libraries, which are screened in biologically relevant assays with dose-response readouts. Ultimately, this results in high rates of true positive and true negative data points, and exceptionally high activity confirmation rates. This approach uncovers novel hits for multiple targets and modalities and constructs robust AIML models with the proprietary screening data generated.

The ability to rapidly produce high-quality datasets at scale to train AIML models opens doors for pursuing “undruggable” targets, novel modalities, and emerging resistance mutations, all with limited and sparse public data available. Beyond optimizing for potency and selectivity, advancements in AI can synergistically optimize molecules throughout the pipeline beyond hit finding, tackling drug metabolism, pharmacokinetics, toxicity and other necessary biological criteria.

Join this webinar to gain insights into how data disrupts the drug discovery paradigm and ultimately delivers new medicines to patients faster.

Join experts from 1859, Sara Thrall Cortese, PhD, Co-founder, Scientific Lead; Andrew MacConnell, PhD, Co-founder, Scientific Fellow; Deirdre Olynick, PhD, MBA, VP Partnerships and Portfolio, for the live webinar on Tuesday, December 5, 2023, at 10am PST (1pm EST).

For more information, or to register for this event, visit Powering the AI Revolution for Drug Discovery with High-Quality Empirical Data.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars and digital content to the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps professionals stay current with industry developments, regulations and jobs. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com
For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Media Contact

Vera Kovacevic, Xtalks, +1 (416) 977-6555 x371, vkovacevic@xtalks.com

View original content to download multimedia:https://www.prweb.com/releases/powering-the-ai-revolution-for-drug-discovery-with-high-quality-empirical-data-upcoming-webinar-hosted-by-xtalks-301990504.html

SOURCE Xtalks